DEF: Alto Neuroscience Sets 2026 Annual Meeting Agenda

Alto Neuroscience, Inc. announces its 2026 Annual Meeting of Stockholders to address director elections, auditor ratification, and amendments to its equity incentive and employee stock purchase plans.

Summary

• The Annual Meeting of Stockholders is scheduled for Tuesday, May 12, 2026, at 8:30 a.m. Eastern Time, and will be held virtually.
• Stockholders will vote on the election of two Class II directors, Raymond Sanchez, M.D. and Gwill York, to serve until the 2029 Annual Meeting of Stockholders.
• The Board of Directors recommends the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• A proposal seeks approval for an amendment and restatement of the 2024 Equity Incentive Plan to treat outstanding pre-funded warrants the same as outstanding shares of Common Stock for purposes of calculating the automatic share reserve increase (evergreen feature).
• Another proposal seeks approval for an amendment and restatement of the 2024 Employee Stock Purchase Plan to treat outstanding pre-funded warrants the same as outstanding shares of Common Stock for purposes of calculating the automatic share reserve increase (evergreen feature).
• The Board of Directors approved an expansion of its size from six to seven directors on March 16, 2026, in connection with a $120 million private placement.
• A one-time repricing of certain stock options occurred on July 3, 2025, reducing the exercise price to $2.35 per share for eligible employees and consultants, subject to retention requirements.
• The company completed a $50.0 million private placement on October 19, 2025, issuing common stock and pre-funded warrants.
• As of the record date, March 16, 2026, there were 31,945,516 shares of common stock outstanding and entitled to vote.
• The closing price of the company's common stock on the New York Stock Exchange as of March 16, 2026, was $24.29.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, primarily due to the successful completion of significant capital raises ($120M and $50M) which strengthen the company's financial position, and the proactive adjustments to equity plans to support long-term talent retention, despite the earlier option repricing event.

Positives

• The company successfully completed a $120 million private placement on March 16, 2026, and a $50 million private placement on October 19, 2025, indicating investor confidence and strengthening capital.
• The proposed amendments to the equity incentive and employee stock purchase plans aim to maintain competitive compensation structures, which is crucial for attracting and retaining talent.
• The current stock price of $24.29 (as of March 16, 2026) is significantly higher than the repriced option price of $2.35 (July 3, 2025) and the IPO price of $16.00 (February 2024), suggesting positive market performance since those events.

Negatives

• The one-time repricing of stock options on July 3, 2025, to $2.35 per share indicates that the company's stock price had fallen significantly below previous grant prices, necessitating a reset to re-incentivize employees.

Risks

• The company's ability to attract and retain qualified personnel is dependent on competitive equity awards, which the proposed plan amendments aim to address.
• The effectiveness of corporate governance is subject to the independence and commitment of board members, with five out of six current directors identified as independent.
• Potential adverse tax consequences for participants in equity plans if not structured or managed correctly, as highlighted in the federal income tax consequences section.

Future Outlook

The company aims to continue attracting and retaining qualified personnel through its amended equity incentive and employee stock purchase plans, which are designed to respond to relevant market changes in equity compensation practices. The evergreen features of these plans are set to automatically increase share reserves annually from January 1, 2027, through January 1, 2034, ensuring long-term incentive capacity.

Management Comments

• Our Board believes that combining the positions of Chief Executive Officer and Chair of the Board helps to ensure that the Board and management act with a common purpose.
• Our Board also believes that it is advantageous to have a chair of the board of directors with an extensive history with, and knowledge of, our company.
• The Board knows of no other matters that will be presented for consideration at the Annual Meeting.

Industry Context

StockSavvy.ai notes that Alto Neuroscience's proactive amendments to its equity compensation plans, particularly the inclusion of pre-funded warrants in evergreen calculations, reflect a broader industry trend among growth-oriented biotechnology companies to optimize their incentive structures following significant capital raises. This strategy is crucial for attracting and retaining top scientific and executive talent in a highly competitive sector, especially after recent private placements. The repricing of options in 2025, while a negative signal at the time, is a common tactic to re-align incentives when stock performance lags, and the subsequent rise in stock price suggests a successful re-engagement of the market and employees.

Comparison to Industry Standards

• The company's non-employee director compensation limit of $750,000 (or $1,000,000 for newly appointed directors) is within the competitive range for public biotechnology companies, comparable to peers like Sage Therapeutics or Neurocrine Biosciences, which also use a mix of cash and equity to attract experienced board members.
• The 5% evergreen provision for the Equity Incentive Plan and 1% for the Employee Stock Purchase Plan are standard percentages observed in similar plans across the biotech industry, such as those at Moderna or BioNTech, designed to maintain a sufficient pool of shares for future grants without excessive dilution.
• The option repricing event in July 2025, while not ideal, is a practice seen in the volatile biotech sector, where companies like Atea Pharmaceuticals or CytoDyn have also adjusted option strike prices to restore incentive value after significant stock price declines, aiming to retain key personnel.

Management Changes

Corporate Governance

Related Party Transactions

• In February 2024, during the IPO Directed Share Program, entities affiliated with Steven A. Cohen purchased 1,025,000 shares for $16,400,000.
• Alpha Wave Ventures II, LP purchased 600,000 shares for $9,600,000 during the IPO.
• Entities affiliated with InVivium Capital purchased 56,250 shares for $900,000 during the IPO.
• Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz (spouse of CMO) purchased 17,000 shares for $272,000 during the IPO.
• Robert L. Friedman 2003 Long-Term Trust fbo Andrew Friedman (brother-in-law of CMO) purchased 17,000 shares for $272,000 during the IPO.
• Amit Etkin, M.D., Ph.D. (CEO) purchased 3,125 shares for $50,000 during the IPO.
• Nicholas Smith (CFO) purchased 1,563 shares for $25,008 during the IPO.
• Oran Etkin (sibling of CEO) purchased 938 shares for $15,008 during the IPO.
• Alison Savitz & David Glass (sibling of CMO) purchased 625 shares for $10,000 during the IPO.
• In the October 19, 2025 private placement, entities associated with Perceptive Advisors (5%+ holder) purchased 2,536,354 shares (via pre-funded warrants) for $14,999,744.
• In the October 19, 2025 private placement, Commodore Capital Master LP (5%+ holder) purchased 1,000,000 shares and 1,536,354 shares (via pre-funded warrants) for $14,999,844.
• In the October 19, 2025 private placement, entities associated with Vestal Point Capital, LP (5%+ holder) purchased 1,606,358 shares for $9,500,001.
• In the October 19, 2025 private placement, entities associated with Point72 Asset Management (5%+ holder) purchased 549,544 shares and 549,543 shares (via pre-funded warrants) for $6,499,946.

Stakeholder Impact

• Shareholders will vote on key corporate governance matters, including director elections and equity plan amendments, directly influencing future company direction and potential dilution from equity grants.
• Employees benefit from the proposed amendments to the 2024 Equity Incentive Plan and 2024 Employee Stock Purchase Plan, which aim to maintain competitive compensation and ownership opportunities, enhancing retention and motivation.
• Management's compensation and long-term incentives are directly tied to the equity plans, and the repricing event in 2025 aimed to re-incentivize them.
• Institutional investors, who participated in recent private placements, will be impacted by the equity plan amendments and board composition, which affect their investment value and governance oversight.

Next Steps

• Stockholders to vote on proposals at the Annual Meeting on May 12, 2026.
• Final voting results to be published in a current report on Form 8-K within four business days after the Annual Meeting.
• The amended 2024 Equity Incentive Plan and 2024 Employee Stock Purchase Plan will become effective upon stockholder approval at the Annual Meeting.
• Automatic share reserve increases for the amended equity plans will commence on January 1, 2027, and continue through January 1, 2034.
• Stockholders may submit proposals for the 2027 Annual Meeting by November 26, 2026 (for inclusion in proxy materials) or between January 12, 2027, and February 11, 2027 (not for proxy materials).

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting, primarily focused on corporate governance and technical amendments to equity compensation plans. It does not contain new operational or financial performance data that would warrant a change in investment stance. The mention of recent capital raises and an option repricing provides context but does not alter the fundamental investment thesis based on this procedural document alone. Investors should hold and await further operational updates.

Keywords

Alto Neuroscience, Proxy Statement, Annual Meeting, Corporate Governance, Equity Incentive Plan, Employee Stock Purchase Plan, Stock Options, Pre-funded Warrants, Capital Raise, Biotechnology, Pharmaceutical, SEC Filing, ANRO